BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

Arguably, the World's First Real-time Pathogen Detection Device

by Andrii Buvailo, PhD  (contributor )   •   Jan. 9, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   Biopharma insight    # HealthTech   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

In a notable advancement for the fast-moving consumer goods (FMCG) industry, Spore.Bio, a deeptech startup, has recently raised €8 million in a pre-seed funding round. This funding was led by LocalGlobe and will fuel the development and deployment of a groundbreaking technology in the realm of pathogen detection.

#advertisement
AI in Drug Discovery Report 2025

Spore.Bio has developed the world's first real-time pathogen detection device, designed for direct use on the factory floor. This technology leverages advanced machine learning models to identify bacteria concentrations in various products, including food, beverages, pharmaceuticals, and cosmetics. With this system, quality managers can be alerted to potential risks much faster than with traditional methods. Traditionally, quality sampling in factories would take anywhere from five to twenty days, requiring off-site testing in external labs. This process was not only time-consuming but also financially demanding. Spore.Bio’s technology significantly cuts down this time, providing almost real-time insights with unparalleled levels of traceability and transparency. This advancement is not just a step forward in technology but also a crucial development in addressing public health risks, reducing cross-contamination, and minimizing costs. Founded in 2023 by CEO Amine Raji, CTO Maxime Mistretta, PhD. , and COO Mohamed Tazi, Spore.Bio boasts a team of experts from various fields, including microbiology, machine learning, optics, photonics, and chemometrics. This team has been instrumental in developing the first functional version of their technology in less than eight months and has already begun signing commercial contracts. Their effort has culminated in a waitlist for their first prototypes, which is already oversubscribed, signaling strong market interest.

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: HealthTech   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.